- Home
- DSY vs PLRX Comparison
DSY vs PLRX Comparison
Compare DSY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- PLRX
- Stock Information
- Founded
- DSY 2020
- PLRX 2015
- Country
- DSY China
- PLRX United States
- Employees
- DSY N/A
- PLRX N/A
- Industry
- DSY
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- PLRX Health Care
- Exchange
- DSY Nasdaq
- PLRX Nasdaq
- Market Cap
- DSY 77.6M
- PLRX 84.7M
- IPO Year
- DSY N/A
- PLRX 2020
- Fundamental
- Price
- DSY $1.29
- PLRX $1.28
- Analyst Decision
- DSY
- PLRX Hold
- Analyst Count
- DSY 0
- PLRX 10
- Target Price
- DSY N/A
- PLRX $9.79
- AVG Volume (30 Days)
- DSY 11.3K
- PLRX 950.8K
- Earning Date
- DSY 02-10-2025
- PLRX 08-06-2025
- Dividend Yield
- DSY N/A
- PLRX N/A
- EPS Growth
- DSY 120.37
- PLRX N/A
- EPS
- DSY 0.01
- PLRX N/A
- Revenue
- DSY $7,323,356.00
- PLRX N/A
- Revenue This Year
- DSY N/A
- PLRX N/A
- Revenue Next Year
- DSY N/A
- PLRX N/A
- P/E Ratio
- DSY $102.83
- PLRX N/A
- Revenue Growth
- DSY 16.37
- PLRX N/A
- 52 Week Low
- DSY $0.75
- PLRX $1.10
- 52 Week High
- DSY $6.98
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- DSY 42.27
- PLRX 36.66
- Support Level
- DSY $1.27
- PLRX $1.56
- Resistance Level
- DSY $1.39
- PLRX $1.70
- Average True Range (ATR)
- DSY 0.07
- PLRX 0.12
- MACD
- DSY -0.00
- PLRX -0.02
- Stochastic Oscillator
- DSY 45.28
- PLRX 5.68
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.